Related Experiment Video
Updated: Oct 16, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Biography as Biology in Drug Development: Bio-Biographical Response States for Translational Pharmacology
James B Baker1, Arnab Ghatak1, Mark R Cullen2
1Clinica AI, New York City, New York 10014, United States.
Abstract:
Molecular stratification has improved drug development, yet treatment effects remain heterogeneous within apparently similar patients. We propose that selected lived exposures be studied as bio-biographical response states: prospectively measured combinations of experience, candidate mediator biology, and treatment context that may modify efficacy, toxicity, adherence, or end point ascertainment. This Perspective translates the concept into a falsifiable development framework. It defines pathway-specific hypotheses, consolidates trial-feasible measures, uses immuno-oncology as an implementation test case, and specifies stage-appropriate evidentiary gates. The framework does not treat adversity as destiny or assume that association establishes causation. It requires reliable measurement, formal interaction estimates, competing-explanation analyses, independent replication, and a defined decision consequence. Used with these guardrails, biography can complement molecular pharmacology by revealing reproducible host states that otherwise appear as unexplained response heterogeneity.
Related Concept Videos
Biopharmaceutics and Pharmacokinetics: Overview
Drug Biotransformation: Overview
Drug Biotransformation: Overview
Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

